Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(0.61)
# 3,734
Out of 4,829 analysts
11
Total ratings
27.27%
Success rate
-19.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Maintains: Overweight | $91 → $89 | $42.41 | +109.86% | 1 | May 8, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $29 → $26 | $8.80 | +195.45% | 2 | May 7, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $17 → $16 | $6.92 | +131.21% | 4 | Apr 29, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Underweight | $8 | $14.19 | -43.62% | 1 | Apr 17, 2025 | |
| XNCR Xencor | Maintains: Overweight | $37 → $33 | $8.77 | +276.28% | 2 | Feb 28, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Overweight | $34 | $26.84 | +26.68% | 1 | May 3, 2024 |
Merus
May 8, 2025
Maintains: Overweight
Price Target: $91 → $89
Current: $42.41
Upside: +109.86%
Arcus Biosciences
May 7, 2025
Maintains: Overweight
Price Target: $29 → $26
Current: $8.80
Upside: +195.45%
iTeos Therapeutics
Apr 29, 2025
Maintains: Overweight
Price Target: $17 → $16
Current: $6.92
Upside: +131.21%
Bicara Therapeutics
Apr 17, 2025
Initiates: Underweight
Price Target: $8
Current: $14.19
Upside: -43.62%
Xencor
Feb 28, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $8.77
Upside: +276.28%
Kiniksa Pharmaceuticals International,
May 3, 2024
Initiates: Overweight
Price Target: $34
Current: $26.84
Upside: +26.68%